Last reviewed 2026-04-20 · How we verify

ECONAZOLE NITRATE

Econazole Nitrate is a marketed antifungal agent primarily indicated for the treatment of interdigital tinea pedis. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. However, the lack of reported revenue and key trial results poses a significant risk in assessing its competitive landscape and long-term market viability.

At a glance

Approved indications

• Interdigital tinea pedis

Common side effects

• Burning
• Itching
• Stinging
• Erythema
• Pruritic rash

Drug interactions

• Warfarin

Key clinical trials

• Efficacy of Self Vs. Physician Application of Triamcinolone-Econazole in Otomycosis (PHASE4)
• Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis (PHASE3)
• A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail (PHASE2)
• Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream (PHASE1)
• Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary (PHASE1)
• Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis (PHASE3)
• A Study of Econazole Foam 1% in Athlete's Foot (PHASE2)
• Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ECONAZOLE NITRATE CI brief — competitive landscape report
• ECONAZOLE NITRATE updates RSS · CI watch RSS